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Abstract 
Background: Atrial fibrillation (AF) is increasingly prevalent with age, and increasing age is an 
independent risk factor for ischemic stroke. Oral anticoagulant (OAC) therapy use in the extreme 
elderly (age ≥85 years) is challenging. 
Methods: The Fushimi AF Registry is a community-based prospective study of Japanese AF patients 
(79 participating medical institutions in Fushimi-ku, Kyoto). The enrollment of patients was started 
in March 2011, and follow-up data were available for 3,304 patients as of July 2014. We compared 
clinical characteristics and outcomes between the extreme elderly group (n=479, 14.5%) and others. 
Results: The extreme elderly had a higher prevalence of major co-morbidities and risk scores for 
stroke, but received less OAC. After a mean follow-up of 2.0 years, endpoints in the extreme elderly 
group were as follows: all-cause death 17.6, stroke or systemic embolism (SE) 5.1, and major 
bleeding 2.0 per 100 person-years, respectively. The extreme elderly group was associated with a 
higher incidence of combined stroke/SE and all-cause death (hazard ratio (HR) 3.20, 95% confidence 
interval (CI) 2.66-3.84, p<0.01), higher incidences of stroke/SE (HR 2.57, 95% CI 1.77-3.65, 
p<0.01) and mortality (HR 3.48, 95% CI 2.84-4.25, p<0.01), compared with others (aged ≤84). The 
incidence of major bleeding was not significantly different (HR 1.40, 95% CI 0.78-2.36, p=0.25). 
Conclusions: In our community-based prospective cohort, Japanese extreme elderly AF patients had 
a higher incidence of stroke but similar major bleeding risks compared with the younger AF 
population. 
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Clinical Trial Registration: URL: http://www.umin.ac.jp/ctr/index.htm 
Unique identifier: UMIN000005834. 
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Introduction 
Atrial fibrillation (AF) is common among the elderly, and increases the risks for stroke and death1. 
The prevalence of AF increases with age, affecting 10% of those aged 80 years and 18% of those age 
>85 years2. The management of AF in elderly patients is of paramount importance, not only because 
of its increasing prevalence with age, but also because increasing age is an independent risk factor 
for ischemic stroke3. 
The use of oral anticoagulants (OAC) reduces stroke by 64% and all-cause mortality by 26%, 
compared with controls4. Thus, several sets of guidelines recommend that elderly AF patients aged 
over 75 years be offered OAC5. However, OAC therapy remains widely under-used in clinical 
practice, and only 15% to 50% of eligible elderly patients are prescribed warfarin therapy6-9. 
The management of OAC in the extreme elderly (age ≥85 years of age) patients is challenging due 
to the need to balance carefully the risk of thromboembolism with that of hemorrhage. To date, 
clinical trials have not specifically targeted extreme elderly patients, and most study subjects are not 
representative of the extreme elderly. Indeed, data on clinical characteristics and outcomes in the 
extreme elderly are limited, with no previous publications from Asia, including Japan. Our aim was 
to evaluate the clinical characteristics, including the status of OAC therapy and outcomes, in extreme 
elderly AF patients in ‘real-world’ clinical practice.  
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Methods 
The Fushimi AF Registry is a community-based prospective survey of AF patients who visited the 
participating medical institutions in Fushimi district, Kyoto, Japan, which is a densely populated 
urban area with a total population of 283,000. The detailed study design, patient enrollment, 
definition of the measurements, and subjects’ baseline clinical characteristics of the Fushimi AF 
Registry have been previously described (UMIN Clinical Trials Registry: UMIN000005834)10, 11. 
This study was conducted in accordance with the amended Declaration of Helsinki. The study 
protocol was approved by the ethical committees of the National Hospital Organization Kyoto 
Medical Center (the approval number 14-033). Since the present research involves an observational 
study not using human biological specimens, written informed consent was not obtained from each 
patient according to the ethical guidelines for epidemiological research issued by the Ministry of 
Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare, 
Japan. 
Age data were collected at the time of entry into the registry. We defined the extreme elderly as 
those aged ≥85 years. We compared the background and the incidence of clinical events during a 
mean follow-up of 2.0 years (739 days) between the extreme elderly group and others (aged ≤74 
years and aged 75-84 years). Chronic kidney disease (CKD) was diagnosed if there was persistent 
proteinuria or if estimated glomerular filtration rate was <60 mL/min/1.73 m2
 
for more than 3 
months12. OAC included warfarin, dabigatran, rivaroxaban and apixaban. The assignment to the 
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OAC group was based on use of OAC at the time of enrollment. The values of prothrombin time 
international normalized ratio (PT-INR) were collected at the time of enrollment for patients taking 
warfarin. Japanese guidelines set different target PT-INR ranges for patients taking warfarin: 1.6~2.6 
for elderly patients (≥70 years old) and 2.0~3.0 for younger patients (<70 years old)13. Anti-platelet 
drugs (APD) included aspirin, clopidogrel, ticlopidine and cilostazol. 
The CHADS2 scoring adds together the points that correspond to the following conditions: 
congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient 
ischemic attack (two points)14. The CHA2DS2-VASc scoring is a refinement of the CHADS2 score 
and extends it by including additional common stroke risk factors: age (patients ≥75 years old get 
two points and patients 65-74 years old get one point), vascular disease and female gender15. We 
assessed hypertension (systolic blood pressure >160 mmHg), abnormal renal function (the presence 
of chronic dialysis or serum creatinine ≥200 mmol/L), abnormal liver function (aspartate 
aminotransferase or alanine aminotransferase 3 times the upper limit normal), stroke history, 
bleeding history, elderly (age >65 years), anti-platelet drugs, and excess alcohol (≥ 8 units alcoholic 
consumption per week) for calculating the HAS-BLED score16. Labile INR data, the values of 
bilirubin, and details on non-steroidal anti-inflammatory drugs were unavailable in our study. 
The primary endpoint in the analysis was the composite of stroke, systemic embolism (SE) and 
all-cause death during the follow-up period. The secondary endpoints were stroke/SE, all-cause death 
and major bleeding. Stroke was defined as the sudden onset of a focal neurologic deficit in a location 
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consistent with the territory of a major cerebral artery, and the diagnosis of ischemic or hemorrhagic 
stroke was confirmed by computed tomography or magnetic resonance imaging. Major bleeding was 
defined as a reduction in the hemoglobin level by at least 2 g/dL, transfusion of at least 2 units of 
blood or symptomatic bleeding in a critical area or organ, following the definition by International 
Society on Thrombosis and Haemostasis17.  
Statistical analysis 
Continuous variables are expressed as mean ± standard deviation (SD). Categorical variables are 
presented as absolute numbers and percentages. We compared continuous variables between the 2 
groups using Student’s t-test or Wilcoxon rank sum test on the basis of the distribution. Comparisons 
of the continuous variables of baseline data between the 3 groups were performed by 1-way analysis 
of variance (ANOVA). We compared categorical variables of baseline data using the Chi-square test 
when appropriate; otherwise, we used Fisher’s exact test. Kaplan-Meier analysis was used to 
estimate event-free survival, and the log-rank test was used to compare survival across the groups. 
The univariate Cox proportional hazard model was used to calculate the hazard ratio (HR) and 95% 
confidence interval (CI) for the incidence of clinical events between each age group. A 2-sided 
P-value <0.05 was considered statistically significant. All statistical analyses were performed with 
JMP10.0 (SAS Institute Inc., Cary, NC, USA). 
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Results 
Of 3,666 patients who were enrolled into the Fushimi AF Registry by the end of July 2013, 
follow-up data (collected every year) were available for 3,304 patients (90.1%) by the end of July 
2014. The age distribution in the entire cohort is shown in Figure 1A. The extreme elderly group 
accounted for 14.5% (479 patients). 
The extreme elderly group was more often female (65.8%), with low body weight (49.0 kg) and 
low body mass index (21.1), and had many co-morbidities such as heart failure, coronary heart 
disease and chronic kidney disease (Table 1).  Mean CHADS2 scores were as follows; 1.35 at age 
≤74 years, 2.61 at age 75-84 years and 2.83 at age ≥85 years (p<0.01). Mean HAS-BLED score were 
as follows; 1.51 at age ≤74 years, 1.88 at age 75-84 years and 1.77 at age ≥85 years (p<0.01). 
Patients whose HAS-BLED scores were ≥3 accounted for 18% (371 patients). 
Figure 1B shows the status of OAC and APD prescription according to age. OAC was used most 
frequently in those aged 75-79 years (60.1%) and its use decreased gradually with increasing age. On 
the other hand, APD were used most frequently in those aged 85-89 years (34.9%). Figure 1C shows 
the distribution of the number of patients according to CHADS2 score in each age group: aged ≤74 
years, aged 75-84 years and the extreme elderly (aged ≥85 years). Figure 1D shows OAC and APD 
prescription according to CHADS2 score in the age groups. In patients aged ≤74 years and 75-84 
years, the use of OAC increased as the CHADS2 score increased, up to about 70% in the high-risk 
patients. In the extreme elderly group, the rate of OAC prescription was generally low, from about 
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30% to 50% in all of the CHADS2 subpopulations, with a weak association with the CHADS2 score. 
In contrast, APD prescription rates were similar in all of the CHADS2 subpopulations, for both the 
extreme elderly group and others.  
The status of OAC therapy in each age group is shown in Table 1. Warfarin was the major OAC 
used in the study period. The prescription rates of OAC were as follows; 51.2% at age ≤74 years, 
60.0% at age 75-84 years and 41.3% at age ≥85 years (p<0.01). The intensities of warfarin control as 
measured by mean PT-INR values at enrollment were comparable among the age groups (1.82 at age 
≤74 years, 1.83 at age 75-84 years and 1.83 at age ≥85 years; p=0.97), but PT-INR values were 
unavailable in more than 30% of the extreme elderly patients. 
The incidence rates of major clinical events in the entire cohort during the mean follow-up of 2.0 
years (a total of 6,694 patient-years) were as follows: composite endpoint of stroke/SE and all-cause 
death in 538 (8.2 per 100 person-years), stroke/SE in 154 (2.3 per 100 person-years), ischemic stroke 
in 116 (1.8 per 100 person-years), all-cause death in 430 (6.4 per 100 person-years) and major 
bleeding in 95 (1.5 per 100 person-years). Kaplan-Meier curves for the incidences of stroke/SE and 
all-cause death, stroke/SE, all-cause death and major bleeding in each age group are shown in Figure 
2. As shown in Table 2, the annual incidence rates of stroke/SE, all-cause death and major bleeding 
in the extreme elderly group were 5.1 per 100 person-years, 17.6 per 100 person-years and 2.0 per 
100 person-years, respectively. The extreme elderly group was significantly associated with a higher 
incidence of stroke/SE (HR 2.57, 95% CI 1.77-3.65, p<0.01), a worse mortality rate (HR 3.48, 95% 
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CI 2.84-4.25, p<0.01), and a higher incidence of the composite of stroke/SE and all-cause death (HR 
3.20, 95% CI 2.66-3.84, p<0.01), compared with those aged ≤84 years. The incidence of major 
bleeding was not significantly different (HR 1.40, 95% CI 0.78-2.36, p=0.25, compared with those 
aged ≤84 years). 
Baseline characteristics, co-morbidities, medications and incidence rates of endpoints in the 
extreme elderly according to OAC use at baseline are shown in Table 3. The mean CHADS2 score 
and CHA2DS2-VASc score were comparable between those with and without OAC (CHADS2 score: 
2.95 vs. 2.74, p=0.06; CHA2DS2-VASc score: 4.66 vs. 4.59, p=0.55), and so were the major 
co-morbidities, except for a higher prevalence of previous stroke in those with OAC (36.4% vs. 
23.5%, p<0.01). The mean HAS-BLED score was also comparable between those with and without 
OAC (1.73 vs. 1.80, p=0.53). 
Kaplan-Meier curves for stroke/SE and all-cause death, stroke/SE, all-cause death and major 
bleeding between patients taking and not taking OAC in the extreme elderly group are shown in 
Figure 3. The incidence rates of the composite of stroke/SE and all-cause death in extreme elderly 
patients were comparable between those with and without OAC (HR 0.94, 95% CI 0.69-1.28, 
p=0.71). The incidences of stroke/SE in those taking OAC were higher than those not taking OAC 
(HR 2.70, 95% CI 1.42-5.41, p<0.01), and the mortality rate was marginally lower, but this was not 
statistically significant (HR 0.75, 95% CI 0.53-1.06, p=0.11). The incidences of major bleeding in 
those with OAC were comparable to that in those without OAC (HR 0.88, 95% CI 0.30-2.45, 
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p=0.81). 
 
 
Discussion 
This is one of the largest community-based prospective cohorts of elderly Asian subjects with AF, 
where we describe the clinical characteristics and outcomes of Japanese extreme elderly (age ≥85) 
patients with AF in ‘real-world’ clinical practice. We found an under-use of OAC, but a high risk of 
stroke/SE and mortality, alongside a similar risk of bleeding. Second, there was a paradoxical finding 
that the incidence of stroke/SE was higher in extreme elderly patients with OAC compared to those 
without OAC use. 
Despite the proven benefit of OAC for preventing stroke in patients with AF, its under-use has 
been reported, particularly among those aged ≥80 years6. Our study shows that the proportion of 
usage of OAC decreases gradually as patients age, and only 41.3% of extreme elderly patients were 
taking OAC. Our study also shows that extreme elderly patients with AF had a weak association with 
OAC prescription according to stroke risk scores, again consistent with a previous report from Japan 
showing modest relationship between CHADS2 risk score and warfarin use18. The decision to 
prescribe long-term OAC therapy in extreme elderly patients with AF remains challenging because 
of the lack of clinical data concerning the risk of both thromboembolism and bleeding. 
Thromboembolism in the extreme elderly with AF 
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One reported study found that the overall annual incidence of ischemic stroke among elderly 
Chinese AF patients aged ≥80 years was as high as 11.3% per year19. Our study showed that the 
incidence of stroke/SE was 5.1 per 100 person-years in Japanese extreme elderly patients with AF, 
which may reflect differences in study populations (hospitalized vs. community setting) and OAC 
use. 
The present study demonstrates the paradoxical finding that the incidence of stroke/SE was higher 
in extreme elderly patients with OAC than in those without OAC use. It was unlikely that 
hemorrhagic stroke was more common in the OAC-treated group (0.7 per 100 person-years in 
patients with OAC vs. 0.6 in patients without OAC). CHADS2 and CHA2DS2-VASc scores were 
comparable between those with and without OAC, but history of stoke were more frequent in those 
with OAC (36.4% vs, 23.5%; p<0.01), and other unidentified risk factors may have been associated. 
Insufficient intensity of warfarin (under-dose of warfarin) may also have been the underlying reason 
for the higher incidence of stroke in OAC-treated patients. The mean PT-INR value was not 
particularly low in the extreme elderly, but PT-INR values were missing in more than 30% of 
patients in the extreme elderly. Particular care is therefore needed when managing this elderly patient 
age group, given their high stroke risk overall, especially the need for careful thromboprophylaxis 
and treatment adherence to optimize stroke prevention in these patients. Indeed, OAC treatment is 
not simply prescribing the drug (ie. warfarin), but paying attention to the quality of anticoagulation 
control, as reflected by the time in therapeutic range (TTR). 
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Bleeding in the extreme elderly with OAC 
Many studies have suggested that the major bleeding risk with OAC therapy is higher in older 
patients than in younger ones. Some studies have reported major bleeding rates with vitamin K 
antagonists in older patients of 1.1–5.1% per year19-24. Another observational study reported a higher 
prevalence of 13.1% per year25. Our study showed that the incidence rate of major bleeding in the 
extreme elderly with OAC was only 1.8 per 100 person-years, and there was no significant difference 
compared with younger age strata. This could have been due to some of the extreme elderly who 
received OAC at enrollment stopping taking OAC at the follow-up. Alternatively, under-dosing of 
warfarin therapy may have decreased the risk of bleeding. Analysis of TTR should be used to assess 
the quality of warfarin control, but unfortunately we do not have data on TTR in this study. 
Benefit-risk balance of OAC in extreme elderly patients with AF 
Several recent studies have demonstrated that OAC therapy provides a net clinical benefit in the 
elderly26-30. However, it is difficult to choose the appropriate OAC therapy in the extreme elderly 
with AF. Although risk scores are useful guides to clinical decision making in practice, in the "real 
world" they do not capture other factors which clinicians and patients consider when starting on long 
term OAC, such as age-related cognitive state, new co-morbidities, general frailty/mobility for 
attending monitoring and even socio-economic factors. Above all, their shorter life expectancy can 
also influence decision-making. In our study, the annual risk of all-cause death was 17.6 per 100 
person-years. Decisions on OAC use in extreme elderly patients with AF should be based on 
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consideration of absolute individual benefits and the risks of treatment and patient preference.  
Study limitations 
This study has several limitations. First, this is an observational study and provides only 
associative evidence, not causative. Second, OAC data were collected only at the time of entry into 
the study, so we were unable to explore the relationship between changes in OAC and clinical events. 
Third, we investigated neither the TTR for patients taking warfarin during follow-up nor the 
adherence of OAC therapies, and therefore it would be difficult to know how the quality of warfarin 
control and the adherence of OAC therapies influenced outcomes. Fourth, about 10% of patients 
were missed during follow-up. As shown in the Supplementary Table, the population with ‘missing 
data’ was older, more often female, and had a higher CHADS2 score than the followed patients, 
which could induce a selection bias. Finally, this study was conducted in Japanese AF patients, and it 
is uncertain whether the study results can be generalizable to other populations. 
 
Conclusions 
Our community-based large prospective cohort shows that Japanese extreme elderly patients with 
AF had a higher incidence of stroke, but similar major bleeding risk, compared with a younger AF 
population. Particular care is therefore needed when managing this elderly patient age group, given 
their high stroke risk overall.  
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Figure Legends 
Figure 1.  
The distribution of age in the entire cohort (A). The distribution of OAC and APD prescription 
according to age (B). The distribution of patients according to CHADS2 score in the extreme elderly 
group (aged ≥85 years) and others (aged ≤74 years, aged 75-84 years) (C). The distribution of OAC 
and APD prescription according to CHADS2 score in the extreme elderly group and others (D). OAC, 
oral anticoagulant; APD, antiplatelet drug. 
Figure 2.  
Kaplan-Meier curves for the incidences of stroke/SE and all-cause death, stroke/SE, all-cause death 
and major bleeding. Data are presented as HR (95% CI). SE, systemic embolism; HR, hazard ratio; 
CI, confidence interval. 
Figure 3.  
The comparison of stroke/SE and all-cause death, stroke/SE, all-cause death and major bleeding in 
the extreme elderly group according to OAC use. Data are presented as HR (95% CI). SE, systemic 
embolism; HR, hazard ratio; CI, confidence interval; OAC, oral anticoagulant.   
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPTYamashita, et al. The extreme elderly with AF (CHEST-15-1095) 
24 
  Table 1. Baseline characteristics, co-morbidities, oral anticoagulant (OAC)  prescription, and warfarin control 
by age category 
  Entire cohort -74 75-84 85- p value 
 Number 3,304 1,606 (48.6%) 1,219 (36.9%) 479 (14.5%)  
 Baseline characteristics        
  Age (years) 73.7 ± 10.9 65.0 ± 8.4 79.1 ± 2.8 88.8 ± 3.6 <0.01 
  Female 1330 (40.3%) 490 (30.5%) 525 (43.1%) 315 (65.8%) <0.01 
  Body weight (kg) 59.1 ± 13.3 63.8 ± 13.2 56.9 ± 11.5 49.0 ± 10.9 <0.01 
  Body mass index (kg/m2) 23.0 ± 4.0 23.7 ± 4.1 22.8 ± 3.6 21.1 ± 3.7 <0.01 
  Systolic blood pressure (mmHg) 124.7 ± 19.0 125.2 ± 18.6 124.0 ± 18.9 125.0 ± 20.5 0.23 
  Diastolic blood pressure (mmHg) 70.6 ± 12.9 73.0 ± 12.5 68.4 ± 12.3 67.7 ± 14.1 <0.01 
  Heart rate (beats/min) 77.7 ± 15.8 77.8 ± 15.7 77.2 ± 15.5 78.6 ± 16.5 0.25 
  Estimated glomerular filtration 
rate (mL/min/1.73 m2) 
61.0 ± 23.1 66.8 ± 24.3 57.4 ± 19.7 51.7 ± 22.3 <0.01 
Calculated creatinine clearance 
(mL/min) 
58.5 ± 35.3 72.3 ± 40.4 50.5 ± 24.3 34.9 ± 18.6 <0.01 
  Hemoglobin (g/dL) 12.9 ± 2.0 13.6 ± 1.9 12.7 ± 1.9 11.5 ± 1.8 <0.01 
  Dialysis 80 (2.4%) 47 (2.9%) 27 (2.2%) 6 (1.3%) 0.07 
  Tobacco history 1063 (46.8%) 621 (55.0%) 358 (43.0%) 84 (27.3%) <0.01 
  Previous catheter ablation 201 (6.1%) 144 (9.0%) 50 (4.1%) 7 (1.5%) <0.01 
Left ventricular ejection fraction 
(%) 
63.1 ± 11.6 63.2 ± 11.4 63.6 ± 11.5 61.7 ± 12.3 0.02 
Left atrial diameter (mm) 43.9 ± 8.5 43.3 ± 8.1 44.5 ± 8.6 44.3 ± 9.3 <0.01 
 Co-morbidities 
  Mean CHADS2 score 2.03 ± 1.33 1.35 ± 1.11 2.61 ± 1.19 2.83 ± 1.20 <0.01 
  Mean CHA2DS2-VASc score 3.36 ± 1.70 2.37 ± 1.44 4.18 ± 1.35 4.62 ± 1.33 <0.01 
  Mean HAS-BLED score* 1.68 ± 0.94 1.51 ± 0.95 1.88 ± 0.90 1.77 ± 0.85 <0.01 
  Heart failure 882 (26.7%) 311 (19.4%) 366 (30.0%) 205 (42.8%) <0.01 
  Hypertension 2028 (61.4%) 958 (59.7%) 781 (64.1%) 289 (60.3%) 0.05 
  Diabetes mellitus 767 (23.2%) 385 (24.0%) 291 (23.9%) 91 (19.0%) 0.06 
  Dyslipidemia 1429 (43.3%) 746 (46.5%) 531 (43.6%) 152 (31.7%) <0.01 
  Coronary heart disease 488 (14.8%) 176 (11.0%) 230 (18.9%) 82 (17.1%) <0.01 
  Chronic kidney disease 1143 (34.6%) 387 (24.1%) 480 (39.4%) 276 (57.6%) <0.01 
  Peripheral arterial disease 138 (4.2%) 52 (3.2%) 67 (5.5%) 19 (4.0%) 0.01  
  History of stroke 612 (18.5%) 232 (14.5%) 242 (19.9%) 138 (28.8%) <0.01 
  History of major bleeding 83 (2.5%) 24 (1.5%) 37 (3.0%) 22 (4.6%) <0.01 
 Medications      
  Aspirin 847 (25.7%) 369 (23.0%) 342 (28.2%) 136 (28.5%) <0.01 
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  Clopidogrel 140 (4.3%) 55 (3.4%) 68 (5.6%) 17 (3.6%) 0.01 
  Digitalis 443 (13.5%) 192 (12.0%) 183 (15.1%) 68 (14.3%) 0.05 
  Verapamil 358 (10.9%) 169 (10.5%) 132 (10.9%) 57 (12.0%) 0.69 
  Beta blocker 942 (28.6%) 487 (30.4%) 359 (29.6%) 96 (20.1%) <0.01 
  Angiotensin converting enzyme 
inhibitor 
298 (9.1%) 121 (7.5%) 114 (9.4%) 63 (13.2%) <0.01 
Angiotensin II receptor blocker 1186 (36.0%) 586 (36.5%) 455 (37.6%) 145 (30.4%) 0.02 
  Calcium antagonist 1007 (30.6%) 479 (29.9%) 378 (31.2%) 150 (31.5%) 0.67 
  Statin 763 (23.2%) 374 (23.3%) 306 (25.3%) 83 (17.4%) <0.01 
  Loop diuretic 737 (22.4%) 255 (15.9%) 310 (25.6%) 172 (36.1%) <0.01 
Anti-arrhythmic drug 677 (20.6%) 389 (24.3%) 230 (19.0%) 58 (12.2%) <0.01 
 OAC prescription 1,751 (53.0%) 822 (51.2%) 731 (60.0%) 198 (41.3%) <0.01 
  Details of OAC 
 
   Warfarin 1,623 (49.1%) 748 (46.6%) 690 (56.6%) 185 (38.6%) <0.01 
   Dabigatran 104 (3.2%) 61 (3.8%) 31 (2.5%) 12 (2.5%) 0.11 
   Rivaroxaban 21(0.6%) 12 (0.8%) 8 (0.7%) 1 (0.2%) 0.43 
   Apixaban 3 (0.1%) 1 (0.1%) 2 (0.2%) 0 (0.0%) 0.52 
  Warfarin control 
   PT-INR value 1.83 ± 0.46 1.82 ± 0.47 1.83 ± 0.45 1.83 ± 0.48 0.97 
   Missing value 374 (23.0%) 151 (20.2%) 166 (24.1%) 57 (30.8%) 
 
  Therapeutic range of PT-INR 
-1.6 382 (30.6%) 181 (30.3%) 161 (30.7%) 40 (31.3%)
 
0.38 
  1.6-2.6 803 (64.3%) 385 (64.5%) 338 (64.5%) 80 (62.5%) 
  2.6-3.0 42 (3.4%) 19 (3.2%) 20 (3.8%) 3 (2.3%) 
  3.0- 22 (1.8%) 12 (2.0%) 5 (1.0%) 5 (3.9%) 
  Data are presented as mean ± SD or number (%). 
  ANOVA for continuous variables and the Chi-square test for categorical variables were performed. 
  OAC: oral anticoagulants, PT-INR: prothrombin time international normalized ratio. 
* HAS-BLED scores were unavailable in 1,277 patients due to incomplete data entry (systolic blood pressure data were 
missing in 26 patients, renal function data in 229, liver function data in 226, and alcoholic consumption data in 1,151). 
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  Table 2. Incidence rates (/100 person-years) of major clinical events 
Outcomes 
Extreme elderly 
group (85-) 
Others (-84) 
Extreme elderly (85-) vs. 
Others (-84) 
p value 
 
incidence rates 
(total events) 
incidence 
rates (total 
events) 
HR (95% CI) 
 
 Number 479 (14.5%) 2825 (85.5%)   
Stroke/SE/All-cause death 21.2 (166) 6.4 (372) 3.20 (2.66-3.84) <0.01 
Stroke/SE 5.1 (40) 2.0 (114) 2.57 (1.77-3.65) <0.01 
   Ischemic stroke 4.5 (35) 1.4 (81) 3.16 (2.10-4.66) <0.01 
   Hemorrhagic stroke 0.6 (4) 0.4 (24) 1.44 (0.42-3.73) 0.52 
All-cause death 17.6(142) 4.9 (288) 3.48 (2.84-4.25) <0.01 
Major bleeding 2.0(15) 1.4 (80) 1.40 (0.78-2.36) 0.25 
  The log-rank test for incidence rates were performed. 
  SE: systemic embolism, HR: hazard ratio, CI: confidence interval. 
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  Table 3. Baseline characteristics and co-morbidities and incidence rates (/100 person-years) of events in 
the extreme elderly 
  85- With OAC Without OAC p value 
 Number 479 (14.5%) 198 (41.3%) 281 (58.7%)  
 Baseline characteristics      
  Age (years) 88.8 ± 3.6 88.1 ± 3.0 89.4 ± 3.9 <0.01 
  Female 315 (65.8%) 122 (61.6%) 193 (68.7%) 0.12 
  Body weight (kg) 49.0 ± 10.9 50.5 ± 11.3 47.9 ± 10.4 0.02 
  Body mass index (kg/m2) 21.1 ± 3.7 21.4 ± 3.7 20.9 ± 3.7 0.16 
Calculated creatinine clearance 
(mL/min) 
34.9 ± 18.6 36.0 ± 17.3 34.2 ± 19.5 0.31 
  Hemoglobin (g/dL) 11.5 ± 1.8 11.6 ± 1.7 11.3 ± 1.9 0.09 
  Dialysis 6 (1.3%) 3 (1.5%) 3 (1.1%) 0.67 
  Tobacco history 84 (27.3%) 36 (29.8%) 48 (25.7%) 0.43 
  Previous catheter ablation 7 (1.5%) 4 (2.0%) 3 (1.1%) 0.40 
Left ventricular ejection fraction (%) 61.7 ± 12.3 61.5 ± 12.5 61.8 ± 12.1 0.87 
Left atrial diameter (mm) 44.3 ± 9.3 46.1 ± 9.2 43.0 ± 9.1 <0.01 
 Co-morbidities 
  Mean CHADS2 score 2.83 ± 1.20 2.95 ± 1.21 2.74 ± 1.18 0.06 
  Mean CHA2DS2-VASc score 4.62 ± 1.33 4.66 ± 1.34 4.59 ± 1.31 0.55 
  Mean HAS-BLED score 1.77 ± 0.85 1.73 ± 0.85 1.80 ± 0.86 0.55 
  Heart failure 205 (42.8%) 87 (43.9%) 118 (42.0%) 0.71 
  Hypertension 289 (60.3%) 112 (56.6%) 177 (63.0%) 0.18 
  Diabetes mellitus 91 (19.0%) 34 (17.2%) 57 (20.3%) 0.41 
  Dyslipidemia 152 (31.7%) 59 (29.8%) 93 (33.1%) 0.49 
  Coronary heart disease 82 (17.1%) 26 (13.1%) 56 (19.9%) 0.06 
  Chronic kidney disease 276 (57.6%) 119 (60.1%) 157 (55.9%) 0.40  
  Peripheral arterial disease 19 (4.0%) 6 (3.0%) 13 (4.6%) 0.48  
  History of stroke 138 (28.8%) 72 (36.4%) 66 (23.5%) <0.01 
  History of major bleeding 22 (4.6%) 7 (3.5%) 15 (5.3%) 0.39 
 Medications     
  Aspirin 136 (28.5%) 40 (20.2%) 96 (34.4%) <0.01 
  Clopidogrel 17 (3.6%) 2 (1.0%) 15 (5.4%) <0.01 
  A combination of aspirin and 
clopidogrel 
11 (2.3%) 2 (1.0%) 9 (3.2%) 0.09 
  Anti-arrhythmic drug 58 (12.2%) 26 (13.1%) 32 (11.5%) 0.59 
 Institutions in which patients were treated 
  Cardiovascular center 164 (34.2%) 58 (29.3%) 106 (37.7%) 0.05 
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 Incidence rates (/100 person-years) 
  Stroke/SE/All-cause death 21.2 20.4 21.8 0.71 
  Stroke/SE 5.1 8.0 2.9 <0.01 
   Ischemic stroke 4.5 7.3 2.2 <0.01 
   Hemorrhagic stroke 0.6 0.7 0.6 0.76  
  All-cause death 17.6 14.6 19.9 0.11 
  Major bleeding 2.0 1.8 2.1 0.81 
Data are presented as mean ± SD or number (%). Student’s t-test or Wilcoxon rank sum test on the basis of the 
distribution for continuous variables, the Chi-square test when appropriate; otherwise, Fisher’s exact test for 
categorical variables, and the log-rank test for incidence rates were performed. 
OAC: oral anticoagulants, SE: systemic embolism. 
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  Supplementary Table. Baseline characteristics, co-morbidities and medications in follow-up cases and 
missing cases. 
  Entire 
Missing 
cases 
Follow-up cases p value 
 Number 3,666 362 (9.9%) 3304 (90.1%)  
 Baseline characteristics 
    
  Age (years) 73.9 ± 11.0 75.4 ± 11.8 73.7 ± 10.9 <0.01 
  Female 1501 (40.9%) 171 (47.2%) 1330 (40.3%) 0.01 
  Body weight (kg) 58.8 ± 13.3 56.2 ± 12.6 59.1 ± 13.3 <0.01 
  Body mass index (kg/m2) 22.9 ± 4.0 22.4 ± 3.8 23.0 ± 4.0 0.02 
  Systolic blood pressure (mmHg) 125.1 ± 19.2 128.8 ± 20.5 124.7 ± 19.0 <0.01 
  Diastolic blood pressure (mmHg) 70.7 ± 12.9 72.3 ± 13.2 70.6 ± 12.9 0.02 
  Heart rate (beats/min) 78.0 ± 16.0 80.6 ± 17.8 77.7 ± 15.8 <0.01 
  Estimated glomerular filtration rate 
(mL/min/1.73 m2) 
61.0 ± 23.1 61.6 ± 23.5 61.0 ± 23.1 0.66 
  Hemoglobin (g/dL) 12.9 ± 2.0 12.8 ± 2.1 12.9 ± 2.0 0.19 
  Dialysis 94 (2.6%) 14 (3.9%) 80 (2.4%) 0.11 
Left ventricular ejection fraction (%) 63.0 ± 11.6 61.6 ± 11.5 63.1 ± 11.6 0.05 
Left atrial diameter (mm) 43.7 ± 8.4 41.8 ± 8.0 43.9 ± 8.5 <0.01 
 Co-morbidities 
  Mean CHADS2 score 2.04 ± 1.34 2.19 ± 1.42 2.03 ± 1.33 0.03 
  Mean CHA2DS2-VASc score 3.38 ± 1.72 3.59 ± 1.86 3.36 ± 1.70 0.02 
  Heart failure 998 (27.2%) 116 (32.0%) 882 (26.7%) 0.03 
  Hypertension 2258 (61.6%) 230 (63.3%) 2028 (61.4%) 0.53 
  Diabetes mellitus 837 (22.8%) 70 (19.3%) 767 (23.2%) 0.10  
  Dyslipidemia 1557 (42.5%) 128 (35.4%) 1429 (43.3%) <0.01 
  Coronary heart disease 540 (14.7%) 52 (14.4%) 488 (14.8%) 0.88 
  Chronic kidney disease 1261 (34.4%) 118 (32.6%) 1143 (34.6%) 0.48 
  History of stroke 683 (18.6%) 71 (19.6%) 612 (18.5%) 0.52 
  History of major bleeding 89 (2.4%) 6 (1.7%) 83 (2.5%) 0.37 
 Medications 
    
  Aspirin 916 (25.1%) 69 (19.1%) 847 (25.7%) <0.01 
  Clopidogrel 157 (4.3%) 17 (4.7%) 140 (4.3%) <0.01 
  Warfarin  1,731 (47.4%) 108 (29.8%) 1,623 (49.1%) <0.01 
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  Data are presented as mean ± SD or number (%). 
  Student’s t-test for continuous variables and the Chi-square test for categorical variables were performed. 
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Figure 3
Stroke/SE/All-cause death
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